This week in techniques

Approach	Summary	Licensing status	Publication and contact information
Drug delivery			
Ultrasound-activated liposomes for delivery of chemotherapeutics to solid tumors	<p>Ultrasound-activated liposomes could be used to deliver chemotherapeutics to solid tumors. In mice with xenograft prostate tumors, animals injected with phosphatidylethanolamine-based liposomes loaded with doxorubicin and exposed to low-frequency ultrasound had less tumor growth than controls given doxorubicin-loaded liposomes without ultrasound. Upcoming publications from Epitarget A/S and collaborators include <i>in vivo</i> studies comparing the company's second-generation ultrasound-activated liposomes with Caelyx doxorubicin, a liposomal doxorubicin formulation from Johnson & Johnson that is approved to treat multiple cancers.</p> <p>SciBX 4(19); doi:10.1038/scibx.2011.554 Published online May 12, 2011</p>	Patented by Epitarget; available for licensing	<p>Hagtvet, E. <i>et al. J. Drug Target.</i>; published online April 28, 2011; doi:10.3109/1061186X.2010.551401</p> <p>Contact: Dag Rune Olsen, University of Bergen, Bergen, Norway e-mail: dag.olsen@mnfa.uib.no</p>